| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Classification | Synthetic gastric pentadecapeptide | Synthetic Thymosin β-4 fragment |
| CAS Number | 137525-51-0 | 77591-33-4 |
| Molecular Weight | 1,419.5 g/mol | 4,963.4 g/mol |
| Primary research mechanism | VEGFR2 / nitric-oxide angiogenic signaling | Actin sequestration via the LKKTETQ motif |
| Studied for | Angiogenesis, fibroblast migration, gut-epithelium models | Cytoskeletal dynamics, cell migration, angiogenesis |
| Size | 15 amino acids | ~43-residue fragment region |
Mechanistic difference. BPC-157 is studied primarily for angiogenic signaling through the VEGFR2 pathway and nitric-oxide system, alongside effects on fibroblast and tendon-cell migration. TB-500, a fragment of Thymosin β-4, is studied for its actin-binding LKKTETQ motif, which regulates the cytoskeleton and directed cell migration. Both intersect at cell migration and angiogenesis, which is why they appear together in tissue-repair research.
Why researchers compare them. Because their mechanisms are complementary rather than overlapping, they are frequently studied as a pair in regenerative-biology models — one acting largely on angiogenic signaling, the other on cytoskeletal organization.
View both compounds
Full mechanism, specifications, and certificates of analysis for each compound.
Frequently asked questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric peptide studied for VEGFR2-mediated angiogenic signaling; TB-500 is a Thymosin β-4 fragment studied for actin regulation and cell migration. They act through distinct but complementary mechanisms in regenerative research models. Both are Research Use Only.
Are BPC-157 and TB-500 studied together?
Yes. Because their research mechanisms are complementary — angiogenic signaling versus cytoskeletal/cell-migration regulation — they are frequently investigated together in tissue-repair models.